Targeted therapy: An evolving world of lung cancer
Publication in refereed journal

香港中文大學研究人員
替代計量分析
.

其它資訊
摘要Lung cancer remains one of the most fatal illnesses. Recent development in cancer genomics and molecular targeted therapy leads to a paradigm shift in management of advanced-stage non-small cell lung cancer. Patients with activated mutation of epidermal growth factor receptor (EGFR) responded dramatically to EGFR tyrosine kinase inhibitor such as gefitinib or erlotinib. Multiple randomized studies have showed EGFR tyrosine kinase inhibitor to be superior to standard first-line chemotherapy in this biomarker-selected population. As the vasculature is considered to be the 'Achillus heel' of the tumour, anti-angiogenic treatment is considered to be a suitable target. Inhibition of vascular endothelial growth factor may improve the efficacy of chemotherapy, although a practical biomarker has not been identified. We have entered an era of personalized therapy for lung cancer and this evolvement holds great promises for better treatment in future. © 2010 The Authors Respirology © 2010 Asian Pacific Society of Respirology.
著者Lam K.-C., Mok T.S.
期刊名稱Respirology
出版年份2011
月份1
日期1
卷號16
期次1
出版社Blackwell Publishing Inc.
出版地United Kingdom
頁次13 - 21
國際標準期刊號1323-7799
電子國際標準期刊號1440-1843
語言英式英語
關鍵詞Anti-angiogenesis, Bevacizumab, Epidermal growth factor receptor, Gefitinib, Lung cancer

上次更新時間 2020-30-11 於 23:47